| [1] |
国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022版)[J]. 临床肝胆病杂志, 2022, 38(2):288-303.
|
| [2] |
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma[J]. Hepatology, 2018, 67(1): 358-380.
|
| [3] |
中国医师协会器官移植医师分会, 中华医学会器官移植学分会肝移植学组. 中国肝癌肝移植临床实践指南(2021版)[J]. 中华消化外科杂志, 2022, 21(4):433-443.
|
| [4] |
Shimamura T, Goto R, Watanabe M, et al. Liver transplantation for hepatocellular carcinoma: how should we improve the thresholds?[J]. Cancers, 2022, 14(2):419-455.
|
| [5] |
Yoneda N, Matsui O, Kobayashi S, et al. Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma[J]. Jpn J Radiol, 2019, 37(3):191-208.
|
| [6] |
Chianchiano P, Pezhouh MK, Kim A, et al. Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations[J]. Hum Pathol, 2018(72):127-134.
|
| [7] |
Cunha GM, Hosseini M, Furlan A, et al. Hepatocellular carcinoma staging: differences between radiologic and pathologic systems and relevance to patient selection and outcomes in liver transplantation[J]. AJR Am J Roentgenol, 2022, 218(1):77-86.
|
| [8] |
Pommergaard HC, Rostved AA, Adam R, et al. Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry[J]. HPB, 2018, 20(8):768-775.
|
| [9] |
Antwi SO, Habboush YY, Chase LA, et al. Response to loco-regional therapy predicts outcomes after liver transplantation for combined hepatocellular-cholangiocarcinoma[J]. Ann Hepatol, 2018, 17(6):969-979.
|
| [10] |
Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma[J]. Liver Int, 2019, 39(12):2214-2229.
|
| [11] |
Cillo U, Giuliani T, Polacco M, et al. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation[J]. World J Gastroenterol, 2016, 22(1):232-252.
|
| [12] |
Singh AK, Kumar R, Pandey AK. Hepatocellular carcinoma: causes, mechanism of progression and biomarkers[J]. Curr Chem Genom Transl Med, 2018(12):9-26.
|
| [13] |
Najjar M, Agrawal S, Emond JC, et al. Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2018(5):17-28.
|
| [14] |
Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET[J].J Nucl Med, 1995, 36(10):1811-1817.
|
| [15] |
Hong G, Suh KS, Suh SW, et al. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation[J]. J Hepatol, 2016, 64(4):852-859.
|
| [16] |
Lai Q, Avolio AW, Graziadei I, et al. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation[J]. Liver Transpl, 2013, 19(10):1108-1118.
|
| [17] |
Halazun KJ, Sapisochin G, von Ahrens D, et al. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria[J]. Int J Surg, 2020(82S):61-69.
|
| [18] |
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J]. Lancet Oncol, 2009, 10(1):35-43.
|
| [19] |
Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[J]. Hepatology, 2001, 33(6):1394-1403.
|
| [20] |
Kamarajah SK, Frankel TL, Sonnenday C, et al. Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with hepatocellular carcinoma (HCC):a surveillance, epidemiology, end results (SEER) analysis[J]. J Surg Oncol, 2018, 117(4):644-650.
|
| [21] |
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update[J]. J Hepatol, 2022, 76(3):681-693.
|
| [22] |
Crocetti L, Bozzi E, Scalise P, et al. Locoregional treatments for bridging and downstaging HCC to liver transplantation[J]. Cancers, 2021, 13(21):5558.
|
| [23] |
Biolato M, Galasso T, Marrone G, et al. Upper limits of downstaging for hepatocellular carcinoma in liver transplantation[J]. Cancers, 2021, 13(24):6337.
|
| [24] |
Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria[J]. Hepatology, 2015, 61(6):1968-1977.
|
| [25] |
Gao Q, Anwar IJ, Abraham N, et al. Liver transplantation for hepatocellular carcinoma after downstaging or bridging therapy with immune checkpoint inhibitors[J]. Cancers, 2021, 13(24):6307.
|
| [26] |
Mehta N, Guy J, Frenette CT, et al. Excellent outcomes of liver transplantation following down-staging of hepatocellular carcinoma to within Milan criteria: a multicenter study[J]. Clin Gastroenterol Hepatol, 2018, 16(6):955-964.
|
| [27] |
Sinha J, Mehta N, Dodge JL, et al. Are there upper limits in tumor burden for down-staging of hepatocellular carcinoma to liver transplant? analysis of the all-comers protocol[J]. Hepatology, 2019, 70(4):1185-1196.
|
| [28] |
Vitale A, Volk M, Cillo U. Transplant benefit for patients with hepatocellular carcinoma[J]. World J Gastroenterol, 2013, 19(48):9183-9188.
|
| [29] |
Kanneganti M, Mahmud N, Kaplan DE, et al. Survival benefit of liver transplantation for hepatocellular carcinoma[J]. Transplantation, 2020, 104(1):104-112.
|
| [30] |
Zheng S, Xie Q, Cheng J. Salvage liver transplant for hepatocellular carcinoma: rescues and benefits[J]. Transl Gastroenterol Hepatol, 2018(3):65.
|
| [31] |
Lai Q, Vitale A, Iesari S, et al. Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer[J]. Hepatology, 2017, 66(6):1910-1919.
|
| [32] |
Sasaki K, Firl DJ, Hashimoto K, et al. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis[J]. Lancet Gastroenterol Hepatol, 2017, 2(8):595-603.
|
| [33] |
Firl DJ, Sasaki K, Agopian VG, et al. Charting the path forward for risk prediction in liver transplant for hepatocellular carcinoma: international validation of HALTHCC among 4,089 patients[J]. Hepatology, 2020, 71(2):569-582.
|